Investing.com - Paratek Pharma (NASDAQ: PRTK) reported first quarter EPS of $-0.350, worse than the analyst estimate of $-0.340. Revenue for the quarter came in at $31.24M versus the consensus estimate of $33.8M.
Guidance
Paratek Pharma sees FY 2023 revenue of $143.000M-$158.000M versus the analyst consensus of $158.970M.
Paratek Pharma's stock price closed at $1.690. It is down -14.650% in the last 3 months and down -12.890% in the last 12 months.
Paratek Pharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Paratek Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Paratek Pharma's Financial Health score is "fair performance".
Check out Paratek Pharma's recent earnings performance, and Paratek Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar